Mankind Pharma (MANKIND)

FairStock Score: 58/100 — STEADY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Mankind Pharma as a seasoned value investor would: first ask what I am getting, then what I am paying. At ₹2425.20, market cap is ₹1.00 lakh Cr, P/E 49.02 and P/B 6.14 against book value of ₹394.85. Graham Number is ₹587.08, so margin of safety is -282.85%—Mr. Market is pricing in a lot. The business itself has decent quality: ROE 12.41%, ROCE 15.98%, debt/equity 0.38, promoter holding 72.66%, and a Piotroski F-Score of 8/9. Sales grew 15.06%, profit 35.31%, and five-year revenue CAGR is 15.79%; latest quarter sales were ₹3,567 Cr and net profit ₹414 Cr. That is steady, but not explosive enough to justify an EV/EBITDA of 208.33. The biggest red flag is free cash flow of -₹10,211 Cr; I want businesses that convert profits into cash. Altman Z-Score 3.43 suggests balance-sheet safety, and FairStock Score 58/100 rates it STEADY. The 52-week range is ₹1909.70–₹2640.30, so current price is nearer the top. Dividend yield is only 0.08%, giving little consolation. As Buffett, I like the franchise and promoter skin in the game; as Graham, I need a margin of safety, which is absent. I would classify it as a Stalwart to monitor, not buy at this valuation. I would wait for either price closer to the lower end of the 52-week range or evidence that free cash flow is turning positive before considering it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer